Literature DB >> 11517184

Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Y L Ma1, R L Cain, D L Halladay, X Yang, Q Zeng, R R Miles, S Chandrasekhar, T J Martin, J E Onyia.   

Abstract

Continuous infusion of PTH in vivo results in active bone resorption. To investigate the molecular basis of the catabolic effect of PTH in vivo, we evaluated the role of OPG and RANKL, which are known to influence osteoclast formation and function. Weanling rats fed a calcium-free diet were parathyroidectomized and infused with PTH via an Alzet pump to examine: 1) the changes of serum-ionized calcium and osteoclast number, 2) the expression of OPG/RANKL mRNA and protein, and 3) the expression of osteoblast phenotype bone formation-associated genes such as osteoblast specific transcription factor, osteocalcin, bone sialoprotein, and type I collagen. PTH (1--38) (0.01--20 microg/100 g) continuous infusion for 1--24 h resulted in a dose-dependent increase in serum-ionized calcium in parathyroidectomized rats and a corresponding dose-dependent increase in osteoclast number, indicating an increased bone resorption. At 20 microg/100 g PTH dose level, serum-ionized calcium was 2.1-fold of the vehicle control and not different from the Sham-parathyroidectomized rats, and osteoclast number was 3-fold of the vehicle control and 1.7-fold of the Sham-parathyroidectomized rats. In the distal femur, RANKL mRNA expression was increased (27-fold) and OPG mRNA expression was decreased (4.6-fold). The changes in RANKL and OPG mRNA levels were rapid (as early as 1 h), dose dependent, and sustained over a 24-h period that was examined. Immunohistochemical evaluation of bone sections confirmed that OPG level was reduced in proximal tibial metaphysis upon PTH infusion. Circulating OPG protein level was also decreased by 32% when compared with the parathyroidectomized control. The expression of genes that mark the osteoblast phenotype was significantly decreased [osteoblast specific transcription factor (2.3-fold), osteocalcin (3-fold), bone sialoprotein (2.8-fold), and type I collagen (5-fold)]. These results suggest that the catabolic effect of PTH infusion in vivo in this well-established resorption model is associated with a reciprocal expression of OPG/RANKL and a co-ordinate decrease in the expression of bone formation-related genes. We propose that the rapid and sustained increase in RANKL and decrease in OPG initiate maintain and favor the cascade of events in the differentiation/recruitment and activation of osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517184     DOI: 10.1210/endo.142.9.8356

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  118 in total

1.  Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells.

Authors:  Chad M Novince; Amy J Koh; Megan N Michalski; Julie T Marchesan; Jason Wang; Younghun Jung; Janice E Berry; Matthew R Eber; Thomas J Rosol; Russell S Taichman; Laurie K McCauley
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

Review 2.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

Review 3.  Cellular and molecular mechanisms of bone remodeling.

Authors:  Liza J Raggatt; Nicola C Partridge
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

4.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 5.  Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development.

Authors:  Yongmei Wang; Daniel D Bikle; Wenhan Chang
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

6.  The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice.

Authors:  Yingben Xue; Yongjun Xiao; Jingning Liu; Andrew C Karaplis; Martin R Pollak; Edward M Brown; Dengshun Miao; David Goltzman
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-24       Impact factor: 4.310

7.  Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor.

Authors:  Ryo Hanyu; Vanessa L Wehbi; Tadayoshi Hayata; Shuichi Moriya; Timothy N Feinstein; Yoichi Ezura; Masashi Nagao; Yoshitomo Saita; Hiroaki Hemmi; Takuya Notomi; Tetsuya Nakamoto; Ernestina Schipani; Shu Takeda; Kazuo Kaneko; Hisashi Kurosawa; Gerard Karsenty; Henry M Kronenberg; Jean-Pierre Vilardaga; Masaki Noda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-25       Impact factor: 11.205

Review 8.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

Review 9.  Role of osteoclasts in regulating hematopoietic stem and progenitor cells.

Authors:  Takeshi Miyamoto
Journal:  World J Orthop       Date:  2013-10-18

10.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.